Abstract

Malignant Pleural Mesothelioma (MPM) is an aggressive tumor of the pleural lining that is usually identified at advanced stages and resistant to current therapies. Appropriate pre-clinical mouse tumor models are of pivotal importance to study its biology. Usually, tumor cells have been injected intraperitoneally or subcutaneously. Using three available murine mesothelioma cell lines with different histotypes (sarcomatoid, biphasic, epithelioid), we have set up a simplified model of in vivo growth orthotopically by inoculating tumor cells directly in the thorax with a minimally invasive procedure. Mesothelioma tumors grew along the pleura and spread on the superficial areas of the lungs, but no masses were found outside the thoracic cavity. As observed in human MPM, tumors were highly infiltrated by macrophages and T cells. The luciferase-expressing cells can be visualized in vivo by bioluminescent optical imaging to precisely quantify tumor growth over time. Notably, the bioluminescence signal detected in vivo correctly matched the tumor burden quantified with classical histology. In contrast, the subcutaneous or intraperitoneal growth of these mesothelioma cells was considered either non-representative of the human disease or unreliable to precisely quantify tumor load. Our non-invasive in vivo model of mesothelioma is simple and reproducible, and it reliably recapitulates the human disease.

Highlights

  • Malignant Mesothelioma is an aggressive and rare cancer arising from the mesothelial cells that line the pleura, the peritoneum, or the pericardial cavity

  • We investigated the in vivo tumor growth of these murine mesothelioma cell lines

  • Tumor growth developed over time in 94% of mice; only few (3/50) mice mice had detectable but very slow growing tumors

Read more

Summary

Introduction

Malignant Mesothelioma is an aggressive and rare cancer arising from the mesothelial cells that line the pleura, the peritoneum, or the pericardial cavity. Eighty percent of the cases are of pleural origin and have been defined as Malignant Pleural Mesothelioma (MPM) [1]. Mesothelioma incidence is strongly related to occupational or environmental exposure to airborne asbestos, with 1400 new cases/year in Italy. It is characterized by a non-resolving, long-lasting inflammation driven by the Cancers 2020, 12, 2136; doi:10.3390/cancers12082136 www.mdpi.com/journal/cancers. In 1992, and its use is restricted in several Western countries, MPM incidence is still growing, and the peak is expected around 2020–2025. MPM has a very long latency period, up to 20–30 years, and it is usually identified at advance stages, because biomarkers and radiological diagnostic tools are not effective for its early detection [4]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.